Investment Rating - The report assigns a "Buy" rating to the company with a current price of HKD 12.20 and a fair value of HKD 18.74 [5]. Core Insights - The company is approaching commercialization of its first product, ABSK021, which has received approval from China's NMPA and is under review by the FDA for a specific indication [5]. - The company reported a revenue of RMB 612 million for 2025, reflecting a year-over-year growth of 21%, alongside a significant increase in adjusted profit [5]. - The company has a robust pipeline with multiple candidates in various stages of clinical development, which supports future growth potential [5]. Financial Forecast - The forecasted revenues for 2026, 2027, and 2028 are RMB 571 million, RMB 375 million, and RMB 726 million, respectively, with corresponding EPS of RMB 0.12, -0.29, and -0.03 [4][5]. - The company is expected to experience a dramatic revenue growth rate of 2,544.2% in 2024, followed by a more moderate growth of 21.5% in 2025, and a decline in subsequent years [4][8]. - The EBITDA for 2024 is projected at RMB 103 million, with a significant drop expected in 2027 to -RMB 199 million [4].

Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical industry [2]. Core Insights - During the period from March 9 to March 15, 2026, a total of 98 innovative drugs/improved new drugs were submitted for clinical trials or market approval, with 82 domestic and 16 imported applications [8]. - A total of 86 innovative drugs/improved new drugs received "implied permission" for clinical trials, including 48 chemical drugs and 37 biological drugs [8]. - Notable drugs include SG-12 injection for chronic hepatitis B and SKB-575 injection for atopic dermatitis, both of which received clinical trial approval [9][10]. Summary by Sections 1. Domestic Innovative Drugs/Improved New Drugs - 1.1 Overview: 98 applications for clinical trials or market approval were recorded, with 82 domestic and 16 imported [8]. - 1.2 Clinical Trial Approvals: 86 drugs received implied permission for clinical trials, including significant drugs like SG-12 and SKB-575 [8][9]. - 1.3 Market Approvals: No new drugs were approved for market this week [29]. 2. Domestic Generic Drugs/Biosimilars - 2.1 Overview: 41 applications for generic drugs were submitted, with 36 for new registration and 4 for clinical trials [30]. - 2.2 Consistency Evaluation: 6 products passed consistency evaluation, with a total of 55 products deemed equivalent [31]. 3. Policy and Regulation - 3.1 Policy Overview: The report summarizes key policies affecting the pharmaceutical industry, including the implementation of the Drug Administration Law [3]. - 3.2 Detailed Policy Explanation: Specific regulations and their implications for the industry are discussed [3]. 4. Global Innovative Drug Development - 4.1 Global R&D Overview: The report highlights the progress of the top 10 innovative drugs globally, including significant approvals and clinical trial results [4]. - 4.2 Clinical Trial Outcomes: The report details both successful and failed clinical trials for various drugs, indicating the competitive landscape [4].

Core Viewpoint - The company, He Yu-B (02256), announced that its subsidiary, Shanghai He Yu Biopharmaceutical Technology Co., Ltd., has received Orphan Drug Designation (ODD) from the FDA for its orally administered small molecule FGFR2/3 inhibitor, ABSK061, aimed at treating Achondroplasia (ACH) [1][2][3] Group 1: Product Development - ABSK061 is a highly selective and potent small molecule FGFR2/3 inhibitor, showing strong target inhibition activity and promising pharmacokinetic and safety profiles in preclinical studies [2][3] - The oral administration route is expected to significantly enhance treatment convenience and compliance, particularly for pediatric patients [2] - ABSK061 is currently undergoing a Phase II clinical trial for ACH patients aged 3-12, with the first patient dosed in December 2025 and preliminary data expected in the second half of 2026 [2] Group 2: Regulatory Milestones - The receipt of ODD is a significant milestone that supports the clinical development, registration, and commercialization processes in the U.S. [1] - ODD designation provides multiple potential benefits, including tax credits for clinical trials, fee waivers for NDA/BLA submissions, and a potential seven-year market exclusivity post-approval [1] - The recognition of ABSK061's potential clinical value by the FDA underscores the unmet medical need for ACH treatment [1] Group 3: Market Potential - Achondroplasia is a rare autosomal genetic disorder leading to severe growth and developmental issues, primarily caused by mutations in the FGFR3 gene [1] - Targeted inhibitors like ABSK061 are expected to offer more precise and effective treatment options for ACH patients [1][3] - The development of ABSK061 as a next-generation FGFR inhibitor aims to achieve a broader therapeutic window and improved clinical efficacy compared to first-generation pan-FGFR inhibitors [3]

Investment Rating - The report maintains an "Outperform" rating for the industry [8] Core Insights - The market potential for Achondroplasia (ACH) is estimated to reach $5 billion, with a focus on companies like BridgeBio, Tyra, and Huya [5] - Vosoritide, the first approved drug for ACH, has shown strong commercial performance, with sales expected to approach $1 billion in 2026 [5][22] - The report highlights the promising results of oral FGFR3 inhibitors, particularly BridgeBio's Infigratinib, which has demonstrated significant growth improvement in clinical trials [5][27] Summary by Sections 1. Market Overview - The CITIC Pharmaceutical Index fell by 0.1% during the week of March 9-13, 2026, underperforming the CSI 300 Index by 0.3 percentage points [4] - The pharmaceutical sector has seen a 0.2% increase year-to-date, lagging behind the CSI 300 Index by 0.7 percentage points [4] 2. Achondroplasia (ACH) Market Potential - ACH affects approximately 250,000 people globally, with around 45,000 cases in China, creating a significant unmet clinical need [20] - Vosoritide has shown a notable increase in annual growth rates for children with ACH, with a reported increase of 1.58 cm/year compared to placebo [21] - The success of Vosoritide validates the commercial value of the ACH market, with sales reaching $927 million in 2025 and projected to be between $975 million and $1.025 billion in 2026 [22] 3. Clinical Developments - Infigratinib, an oral FGFR3 inhibitor, has shown a 2.1 cm/year increase in growth rates in clinical trials, with plans to submit a new drug application to the FDA in the second half of 2026 [26][27] - Tyra Biosciences' FGFR3 inhibitor TYRA-300 is expected to disclose preliminary results in the second half of 2026, potentially offering better efficacy through higher dosing [36] - Huya's ABSK061 is currently in Phase II trials for children aged 3-12, with initial results anticipated in late 2026 [36] 4. Weekly Market Performance - The report notes that the pharmaceutical sector's trading volume accounted for 3.3% of the total A-share market, with a decrease of 9% compared to the previous trading period [52] - The top-performing stocks in the pharmaceutical sector included Yingke Medical (+35.2%) and Zhonghong Medical (+25.3%) during the week [53]

Group 1 - The company, He Yu-B (02256), announced that its subsidiary, Shanghai He Yu Biomedical Technology Co., Ltd., has received Rare Pediatric Disease (RPD) designation from the FDA for its orally administered small molecule FGFR2/3 inhibitor, ABSK061, intended for the treatment of Achondroplasia (ACH) [1] - The RPD designation aims to encourage pharmaceutical companies to develop innovative therapies for severe rare diseases primarily affecting individuals under 18 years old, providing economic incentives to accelerate drug approval processes [1] - If the indication for ABSK061 is ultimately approved, the company will have the opportunity to obtain a Priority Review Voucher (PRV), which can expedite the FDA review of other New Drug Applications (NDA) or Biologics License Applications (BLA), thus holding significant strategic and commercial value [1] Group 2 - Achondroplasia (ACH) is a rare genetic disorder that leads to severe growth and developmental disabilities, primarily caused by mutations in the FGFR3 gene, resulting in abnormal activation of FGFR3 that inhibits normal cartilage ossification [2] - ABSK061 is a highly active and selective small molecule FGFR2/3 inhibitor developed by the company, showing significant target inhibition activity, favorable pharmacokinetic characteristics, and safety advantages in preclinical studies [2] - The oral administration of ABSK061 offers significant advantages in convenience and treatment adherence, particularly for pediatric patients, making it a potentially valuable therapeutic candidate for treating children and adolescents with ACH [2] - Currently, ABSK061 is undergoing a Phase II clinical trial targeting children aged 3-12 years with ACH [2]

Core Insights - The treatment landscape for achondroplasia (ACH) is undergoing significant transformation with the introduction of new therapies challenging the existing market leader, Vosoritide [1][4][10] Group 1: Current Market Dynamics - Vosoritide, developed by BioMarin, was the first approved drug for ACH, projected to generate sales of $927 million by 2025, reflecting a 26% year-over-year growth [1][3] - The drug's mechanism involves a C-type natriuretic peptide analog that promotes growth by inhibiting FGFR3 activity, leading to an average height increase of 1.57 cm per year in clinical trials [3][4] - Despite its success, Vosoritide faces competition from several emerging therapies, including Ascendis' TransCon-CNP and BridgeBio's Infigratinib, which are designed to improve efficacy and patient compliance [1][4][10] Group 2: Emerging Competitors - Infigratinib, a small molecule drug from BridgeBio, targets FGFR3 directly and has shown superior clinical results, with an average height increase of 2.1 cm per year, and a more convenient oral administration route [4][7] - The drug's clinical trials reported no serious adverse effects, enhancing its appeal compared to Vosoritide, which requires daily injections [7][9] - Ascendis' TransCon-CNP aims for weekly dosing and has demonstrated an annual height increase of 2.29 cm, indicating a potential edge over Vosoritide [10][11] Group 3: Future Developments - The competitive landscape is intensifying with multiple next-generation therapies in development, including high-selectivity FGFR inhibitors and nucleic acid-based treatments [11][12] - The market is expected to evolve rapidly, with each incremental improvement in efficacy and administration method potentially reshaping the treatment paradigm for ACH [12][13] - The industry is witnessing a shift from overlooked rare diseases to a focus on developing targeted therapies, highlighting the growing recognition of the ACH market's potential [12][13]

Group 1 - The core point of the article is the approval of the CSF-1R inhibitor, Pimitinib, by the Chinese drug regulatory authority for the treatment of symptomatic tenosynovial giant cell tumors (TGCT) in adult patients, marking the company's first self-developed drug to be approved for commercialization [1] - Pimitinib, marketed as Beijiemai, is an oral, highly selective, and effective small molecule CSF-1R inhibitor, which demonstrated the best overall response rate (ORR) in the global Phase III MANEUVER study, with significant safety advantages [1] - Long-term follow-up data presented at the 2025 ESMO showed that the ORR for patients treated with Pimitinib increased from 54% at 25 weeks to 76.2% at a median follow-up of 14.3 months, with four cases achieving complete remission [1] Group 2 - The company has established a commercial partnership with Merck, which will drive the commercialization process of Pimitinib following its approval [1] - The company is also advancing multiple pipeline projects, including the approval of the IND application for the oral small molecule KRAS G12D inhibitor, ABSK141, and the completion of the first patient dosing in the Phase II trial of the FGFR2/3 inhibitor, ABSK061, which is the first selective FGFR2/3 inhibitor to enter clinical trials globally [2] - The company maintains a "buy" rating and forecasts net profits of 63 million, 151 million, and 133 million for the years 2025-2027, corresponding to PE ratios of 131X, 55X, and 62X, respectively, indicating a positive outlook on the commercial journey and pipeline progress [3]

Core Viewpoint - The approval of the CSF-1R inhibitor, Pimitinib, marks a significant milestone for the company as its first self-developed drug, initiating a new phase of commercialization and maintaining a "buy" rating [1] Group 1: Pimitinib Approval and Commercialization - Pimitinib, an oral, highly selective, and effective small molecule CSF-1R inhibitor, has been approved by the China National Medical Products Administration for the treatment of symptomatic tenosynovial giant cell tumors (TGCT) in adult patients [1] - The drug demonstrated a best-in-class overall response rate (ORR) of 76.2% at a median follow-up of 14.3 months, with four patients achieving complete remission [1] - Merck will drive the commercialization process for Pimitinib following its approval, leveraging its strong global commercialization capabilities [1] Group 2: Ongoing Pipeline Developments - The company has announced positive preliminary data for the oral small molecule PD-L1 inhibitor combined with Vomeletinib for treating EGFR-mutant, PD-L1 positive advanced non-small cell lung cancer, showing good safety and tolerability [2] - The IND application for the oral small molecule KRAS G12D inhibitor, ABSK141, has been approved by the China National Medical Products Administration, indicating potential best-in-class oral bioavailability [2] - The FGFR2/3 inhibitor, ABSK061, has completed the first patient dosing in a Phase II clinical trial for treating children with achondroplasia, being the first selective FGFR2/3 inhibitor to enter clinical trials globally [2] Group 3: Profit Forecast - The company maintains its previous profit forecast, expecting net profits attributable to the parent company to be 63 million, 151 million, and 133 million for the years 2025-2027, corresponding to price-to-earnings ratios of 131X, 55X, and 62X respectively [3]

Core Viewpoint - The approval of the CSF-1R inhibitor, Pimitinib, marks the company's first self-developed drug to be commercialized, initiating a new phase in its business journey while maintaining a steady advancement in its pipeline, leading to a positive self-sustaining cycle [1][2]. Group 1: Product Development and Commercialization - Pimitinib (brand name: Beijiemai) is an orally administered, highly selective, and effective small molecule CSF-1R inhibitor, which has shown the best overall response rate (ORR) in its class during the global Phase III MANEUVER study [2]. - The long-term follow-up data presented at the 2025 ESMO showed that the ORR for patients treated with Pimitinib increased significantly from 54% at 25 weeks to 76.2% at a median follow-up of 14.3 months, with four cases achieving complete remission [2]. - The company has established an exclusive commercialization partnership with Merck, which will expedite the commercialization process of Pimitinib [2]. Group 2: Ongoing Research and Development - Preliminary data from the Phase II study of the oral small molecule PD-L1 inhibitor combined with Vomeletinib for EGFR-mutant and PD-L1 positive advanced non-small cell lung cancer showed good safety and tolerability, leading to approval for first-line treatment research by the Chinese regulatory authority [3]. - The company announced several advancements in its pipeline, including the IND approval for the oral small molecule KRAS G12D inhibitor, ABSK141, which demonstrated potential best-in-class oral bioavailability in preclinical studies [3]. - The FGFR2/3 inhibitor, ABSK061, has completed the first patient dosing in a Phase II clinical trial for treating children with achondroplasia, being the first selective FGFR2/3 inhibitor to enter clinical trials globally [3]. Group 3: Financial Forecast - The company maintains its previous profit forecast, expecting net profits attributable to the parent company to be 63 million, 151 million, and 133 million for the years 2025 to 2027, corresponding to price-to-earnings ratios of 131X, 55X, and 62X respectively [4].

Investment Rating - The report maintains a "Buy" rating for the company [2][6]. Core Insights - The approval of the CSF-1R inhibitor, Pimitinib, by the Chinese regulatory authority marks the beginning of a new commercialization journey for the company. This drug is the first self-developed new drug and will be commercialized by Merck [6]. - Pimitinib has shown best-in-class overall response rates (ORR) in clinical trials, with a significant increase from 54% to 76.2% in ORR during a median follow-up of 14.3 months [6]. - The company has multiple ongoing pipeline projects, including the approval of IND for the oral KRAS G12D inhibitor and the completion of the first patient dosing in a clinical trial for the FGFR2/3 inhibitor [6]. Financial Data and Profit Forecast - Revenue projections for the company are as follows: - 2023: 19 million - 2024: 504 million - 2025E: 612 million - 2026E: 756 million - 2027E: 627 million - The net profit attributable to ordinary shareholders is expected to be: - 2023: -432 million - 2024: 28 million - 2025E: 63 million - 2026E: 151 million - 2027E: 133 million - The projected earnings per share (EPS) are: - 2023: -0.67 - 2024: 0.04 - 2025E: 0.09 - 2026E: 0.22 - 2027E: 0.20 [3][7].